|
Breast Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Omeprazole and, to a lesser extent, sulindac and leflunomide were full and partial AHR agonists, respectively, in both breast cancer cell lines.
|
22879383 |
2012 |
|
Breast Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
AHR has also emerged as a potential therapeutic target for the treatment of human diseases and different cancers, including breast cancer.
|
22903824 |
2012 |
|
Breast Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Sunitinib, a tyrosine kinase inhibitor, induces cytochrome P450 1A1 gene in human breast cancer MCF7 cells through ligand-independent aryl hydrocarbon receptor activation.
|
23288144 |
2013 |
|
Breast Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Therefore, we established stable AhR knockdown cells of the human breast cancer cell line MDA-MB-231 and analyzed their tumorigenic properties in in vitro and in vivo model systems.
|
23733406 |
2013 |
|
Breast Carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Expression of estrogen receptor α (ERα) and AhR-mediated transcriptional induction of CYP1A1 can sensitize breast cancer cells to AF.
|
24058584 |
2013 |
|
Breast Carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
To this end, we also evaluated the role of AhR expression on survival of patients diagnosed with breast cancer.
|
24481452 |
2014 |
|
Breast Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Numerous studies have implicated the aryl hydrocarbon receptor (AhR) as a potential therapeutic target for several human diseases, including estrogen receptor alpha (ERα) positive breast cancer.
|
24885022 |
2014 |
|
Breast Carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
We used Affymetrix Human GeneChip 1.0-ST whole transcriptome arrays to analyze alterations of gene expression resulting from stable AhR knockdown in the MDA-MB-231 breast cancer cell line.
|
24932473 |
2014 |
|
Breast Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
DIM is an aryl hydrocarbon receptor (AhR) ligand and a potential anticancer agent, namely for the treatment of breast cancer.
|
25048790 |
2014 |
|
Breast Carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
These data indicate that NK150460 is a novel AhR agonist with selective antitumor activity against breast cancer cell lines, and its features differ from those of the other two AhR agonists.
|
25522763 |
2015 |
|
Breast Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Since AhR agonists often elevate intracellular oxidative stress, we hypothesize that 5F 203 increases reactive oxygen species (ROS) to induce DNA damage, which thwarts breast cancer cell growth.
|
25781201 |
2015 |
|
Breast Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
The AhR interacts with several cell signaling pathways associated with induction of tyrosine kinases, cytokines and growth factors which may support the survival roles of AhR escaping from apoptosis elicited by a variety of apoptosis inducing agents in breast cancer.
|
25987214 |
2015 |
|
Breast Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Previous studies showed anti-metastatic roles of agonist-activated aryl hydrocarbon receptor (Ahr) in various breast cancer cell lines.
|
26377202 |
2015 |
|
Breast Carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
This meta-analysis suggests that Ahr (rs2066853) polymorphism would not modify the risk of breast cancer.
|
26662408 |
2015 |
|
Breast Carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Therefore, understanding if changes in expression and/or activation of the AhR are associated with somatic inactivation of the BRCA-1 gene may provide clues for breast cancer therapy.
|
26715507 |
2015 |
|
Breast Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Aryl Hydrocarbon Receptor Activates NDRG1 Transcription under Hypoxia in Breast Cancer Cells.
|
26852918 |
2016 |
|
Breast Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
These data suggest that the AHR plays an important role in development of cells with cancer stem cell-like qualities and that environmental AHR ligands may exacerbate breast cancer by enhancing expression of these properties.
|
26984638 |
2016 |
|
Breast Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
We investigated the ability of AhR agonist Aminoflavone (AF) and AF pro-drug (AFP464) to disrupt mammospheres derived from breast cancer cells and a M05 mammary mouse model of breast cancer respectively.
|
26996297 |
2016 |
|
Breast Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
In this context, this work investigated the effect of HCB (0.005, 0.05, 0.5, and 5μM) on TGF-β1 signaling and AhR/TGF-β1 crosstalk in the human breast cancer cell line MDA-MB-231 and analyzed whether TGF-β1 pathways are involved in HCB-induced cell migration and invasion.
|
27519288 |
2016 |
|
Breast Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
To examine the roles of estrogen receptor α (ERα) and aryl hydrocarbon receptor (AhR) and their crosstalk in the actions of BEs, we studied gene regulation and proliferation responses to four widely used BEs, genistein, daidzein, and S-equol from soy, and liquiritigen from licorice root in breast cancer and liver cells.
|
27543265 |
2016 |
|
Breast Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Analysis of patients with breast cancer showed a significant positive correlation between intratumoral AhR and aromatase status.
|
27900579 |
2017 |
|
Breast Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Novel Aryl Hydrocarbon Receptor Agonist Suppresses Migration and Invasion of Breast Cancer Cells.
|
27907195 |
2016 |
|
Breast Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Aryl hydrocarbon receptor/cytochrome P450 1A1 pathway mediates breast cancer stem cells expansion through PTEN inhibition and β-Catenin and Akt activation.
|
28103884 |
2017 |
|
Breast Carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
In the present study, the effect of E2/ER on the expression of AhR and CYP1A1 genes was investigated for MCF-7 clonal variant (MCF-7 CV) breast cancer cells expressing ER.
|
28618207 |
2017 |
|
Breast Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
(<i>Z</i>)-2-(3,4-Dichlorophenyl)-3-(1<i>H</i>-Pyrrol-2-yl)Acrylonitrile Exhibits Selective Antitumor Activity in Breast Cancer Cell Lines via the Aryl Hydrocarbon Receptor Pathway.
|
29269419 |
2018 |